Please assess the completion status of the following clinical trial:

Trial Title: Poliovirus Vaccine Trial in Bangladesh

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants of 6 weeks of age (±2 days).~* Study families reside within the Health and Demographic Surveillance System (HDSS) area, service area of the ICDDR,B.~* Family able to understand and comply with planned study procedures~Exclusion Criteria:~* Family residence outside the ICDDR,B HDSS service area, or families expecting to move away during the study period, will be excluded.~* A diagnosis or suspicion of immunodeficiency disorder (either in the infant or in a member of the immediate family).~* A diagnosis or suspicion of bleeding disorder that would contraindicate venipuncture.~* Acute diarrhea, infection or illness at the time of the first visit (6 weeks of age) that would require infant's admission to a hospital or would contraindicate provision of OPV per country guidelines.~* Acute vomiting and intolerance to liquids within 24 hours before the first visit (6 weeks of age).~* Receipt of OPV or IPV at any time before enrollment based upon mother's recall or immunization card if available.~* Because of contact transmission of vaccine poliovirus strains, newborns from multiple births will be excluded from the study to prevent transmission of vaccine strains received during routine immunization from the twin to the study participant.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 6 Weeks
- Healthy Volunteers: t

Study Arms:
- Bivalent OPV 2 week interval (Type: ACTIVE_COMPARATOR): Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
- Bivalent OPV 4 week interval (Type: ACTIVE_COMPARATOR): Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
- Monovalent OPV 2week interval (Type: ACTIVE_COMPARATOR): Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
- Monovalent OPV 4 week interval (Type: ACTIVE_COMPARATOR): Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
- Trivalent OPV 4 week interval (Type: ACTIVE_COMPARATOR): Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).

Based on this trial design, predict the completion outcome and termination type (if applicable).